Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium bicarbonate for critically ill patients with metabolic acidosis and acute kidney injury
2025-523914-10-00Phase 4Authorised
- Sponsor
- Universität Münster
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sodium bicarbonate in metabolic acidosis, acute kidney failure (AKF) and critical illness (2 arms), sponsored by Universität Münster. Primary endpoint: Major adverse kidney events at day 90 (MAKE90). Planned start Apr 2026; status: authorised.
02
Drugs
sodium bicarbonate
03
Conditions
metabolic acidosisacute kidney failure (AKF)critical illness
Beyond the preview
Go deeper on 2025-523914-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523914-10-00.